Levetiracetam-Induced Rhabdomyolysis Case Study
Author Information
Author(s): Muacevic Alexander, Adler John R, Lyles Sierra, Atalay Rediet Tefera, Taylor Shay, Ayele Girma M, Zinabu Samrawit W, Mohammed Ahmad, Michael Miriam B, Poddar Vishal A
Primary Institution: Howard University Hospital
Hypothesis
Can levetiracetam cause rhabdomyolysis in patients who have previously tolerated the medication?
Conclusion
The patient's condition improved rapidly after discontinuing levetiracetam, indicating a strong link between the medication and rhabdomyolysis.
Supporting Evidence
- Levetiracetam-induced rhabdomyolysis is a rare phenomenon with few documented cases.
- The patient's CPK levels peaked at 46,671 U/L after restarting levetiracetam.
- Discontinuation of levetiracetam led to a rapid decrease in CPK levels.
- Monitoring CPK levels is crucial for patients on levetiracetam who show symptoms of rhabdomyolysis.
Takeaway
A man got very sick from a medicine he had taken before without problems, but he got better quickly after stopping it.
Methodology
Case report based on retrospective chart review.
Limitations
The study relied on retrospective data, which may lack comprehensive patient information.
Participant Demographics
47-year-old male with a history of epilepsy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website